Clopidogrel to help prevent systemic sclerosis in high-risk people
Part of Skin clinical trials.
This study tests whether the medicine clopidogrel can lower the chance of developing systemic sclerosis in adults who have certain blood antibodies and symptoms that suggest higher risk. If you qualify, you would take clopidogrel for the study to see whether it delays or prevents the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (age 18 to under 85)
- Have blood tests showing specific positive auto-antibodies related to systemic sclerosis (AAN at least 1/160)
- Have Raynaud’s phenomenon (cold or color-changing fingers) reported by you and confirmed by a doctor
- Be covered by health insurance and agree to sign informed consent
- Not already have a systemic sclerosis diagnosis based on standard 2013 criteria
- No current use of antiplatelet medicines or blood thinners, and no medicines that suppress the immune system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with systemic scleroderma (also called scleroderma) to better understand the condition over time. You may be included if you meet specific diagnosis and blood-test requirements and can give informed consent.
This trial tests if a new drug called telitacicept can safely help people with systemic sclerosis (scleroderma) who still have active disease despite standard treatments. It aims to see if the drug can slow or improve skin thickening and other symptoms.
This trial tests a new investigational medicine called PRO-203 for people with systemic sclerosis (scleroderma). It aims to see if the medicine can help control active disease that hasn't responded to other treatments.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
Hear when a new Scleroderma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.